Tmod-35. Egfrviii Overexpression And Loss Of Mouse Specific Cdkn2A In Glial Cells Leads To Spontaneous Gliomagenesis In A Novel Mouse Model

Olivia Singh,Mathew Voisin,Mira Li,Hafsah Ali,Qingxia Wei,Andrew Gao,Sameer Agnihotri,Kelly Burrell,Mark Wilson,Shirin Kamiri,Severa Bunda,Kenneth Aldape,Gelareh Zadeh
DOI: https://doi.org/10.1093/neuonc/noae165.1299
2024-11-29
Neuro-Oncology
Abstract:A new mouse model for the classical subtype of human glioblastoma (GBM) has been bred using Cre-mediated EGFR vIII overexpression and homozygous p19-ARF deletion, the mouse homolog of human p14ARF/CDKN2A, in GFAP expressing cells. Transgenic mice develop intraparenchymal and/or leptomeningeal brain lesions with some spinal cord invasion as early as 1 month old and 95% of mice die by 6 months due to hydrocephalus and/or paralysis. Mice with high grade tumors have worse survival and similar features to human classical GBM such as necrosis, high levels of mitosis and infiltration of tumor cells into normal brain. Immunohistochemical analysis confirms EGFR vIII overexpression and p19-ARF loss in Cre-expressing cells, along with patchy positive GFAP and high proliferation by Ki67. Bulk RNA sequencing reveals GEC3 tumors cluster closely with human classical GBM and have significant upregulation of downstream markers in the JAK/STAT and P13K/AKT pathways. Adherent and neurosphere primary culture of dissociated tumors indicate that tumor cells maintain EGFR vIII expression in culture and generate xenograft tumors by 3 weeks after intracranial injections into NODSCID mice. Xenograft tumors are reminiscent of the primary tumor, with similar histopathological features and immunohistochemical staining. Our spontaneous glioma model is a powerful tool for future studies focused on the role of the immune microenvironment on glioma recurrence and resistance.
oncology,clinical neurology
What problem does this paper attempt to address?